Abbott Laboratories (NYSE:ABT) announced a quarterly dividend on Friday, September 15th, Wall Street Journal reports. Investors of record on Friday, October 13th will be paid a dividend of 0.265 per share by the healthcare product maker on Wednesday, November 15th. This represents a $1.06 annualized dividend and a yield of 1.91%. The ex-dividend date is Thursday, October 12th.
Abbott Laboratories has raised its dividend payment by an average of 22.9% annually over the last three years and has increased its dividend annually for the last 44 consecutive years. Abbott Laboratories has a payout ratio of 42.6% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Abbott Laboratories to earn $2.81 per share next year, which means the company should continue to be able to cover its $1.06 annual dividend with an expected future payout ratio of 37.7%.
Shares of Abbott Laboratories (NYSE ABT) opened at 55.40 on Wednesday. The stock has a market cap of $96.25 billion, a PE ratio of 77.59 and a beta of 1.06. The company’s 50-day moving average is $52.07 and its 200 day moving average is $47.95. Abbott Laboratories has a 52 week low of $37.38 and a 52 week high of $55.43.
In related news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The shares were sold at an average price of $52.95, for a total value of $3,307,257.00. Following the completion of the sale, the insider now directly owns 113,426 shares in the company, valued at $6,005,906.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jaime Contreras sold 52,700 shares of the business’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the sale, the insider now owns 58,739 shares of the company’s stock, valued at $3,052,665.83. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 333,310 shares of company stock valued at $16,857,255. 0.76% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Abbott Laboratories by 2.6% in the second quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after purchasing an additional 3,241,063 shares during the period. Capital Research Global Investors grew its holdings in Abbott Laboratories by 45.7% in the second quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after purchasing an additional 14,918,038 shares during the period. Northern Trust Corp grew its holdings in Abbott Laboratories by 3.1% in the second quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after purchasing an additional 809,732 shares during the period. Dimensional Fund Advisors LP grew its holdings in Abbott Laboratories by 28.6% in the second quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after purchasing an additional 2,606,404 shares during the period. Finally, FIL Ltd grew its holdings in Abbott Laboratories by 11.1% in the second quarter. FIL Ltd now owns 10,189,243 shares of the healthcare product maker’s stock valued at $495,299,000 after purchasing an additional 1,021,064 shares during the period. Hedge funds and other institutional investors own 71.50% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/10/11/abbott-laboratories-abt-to-issue-quarterly-dividend-of-0-27-on-november-15th.html.
ABT has been the subject of a number of research reports. BidaskClub upgraded shares of Abbott Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Jefferies Group LLC restated a “buy” rating and set a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, June 29th. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Wells Fargo & Company restated an “outperform” rating and set a $54.00 target price (up previously from $47.50) on shares of Abbott Laboratories in a research report on Friday, June 30th. Finally, Cowen and Company restated an “outperform” rating and set a $55.00 target price (up previously from $48.00) on shares of Abbott Laboratories in a research report on Friday, July 14th. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $54.94.
About Abbott Laboratories
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
What are top analysts saying about Abbott Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abbott Laboratories and related companies.